Benjamin A Steinberg1, Paul Dorian2, Kevin J Anstrom3, Rachel Hess4, Daniel B Mark3, Peter A Noseworthy5, John A Spertus6, Jonathan P Piccini3. 1. Department of Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah. Electronic address: benjamin.steinberg@hsc.utah.edu. 2. Division of Cardiology, University of Toronto, St. Michael's Hospital, Toronto, Ontario, Canada. 3. Duke Clinical Research Institute, Durham, North Carolina. 4. Department of Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah. 5. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. 6. Cardiovascular Research, Department of Biomedical and Health Informatics, Saint Luke's Mid-America Heart Institute, Kansas City, Missouri.
Abstract
OBJECTIVES: This study sought to determine how frequently patient-reported outcomes (PROs) are collected in registered clinical studies of atrial fibrillation (AF). BACKGROUND: Improving symptom burden and quality of life are important goals in the treatment of AF and are best measured with PROs. METHODS: Data from Clincaltrials.gov were studied to identify PROs in AF studies. All studies reporting AF as the disease condition were included, and PROs were identified by search terms within the outcome measures field. Generic and AF-specific PROs were identified and assessed by study type and year. Clinicaltrials.gov reporting was compared with published reports of linked studies in PubMed. RESULTS: From 1999 to 2018, 1,709 studies including AF patients were posted; 238 studies (14%) included PROs. Collection of PROs was reported in 22% of trials (n = 83 of 386) studying procedural interventions and 11% of all Phase 3 studies (n = 18 of 168). Among the 238 studies with PROs, most described "quality of life" (n = 194 [82%]), and most (n = 198 [83%]) included only generic (not AF-specific) PROs. Only 17% of studies (n = 40) reporting PROs specified a previously published AF-specific tool, most commonly the AFEQT (Atrial Fibrillation Effect on QualiTy-of-life) form (n = 20 [8.4%]). Among the available PubMed citations of 391 studies, 74 studies (19%) described collecting a specific PRO tool (n = 29 [7.4%]) for an AF-specific PRO. CONCLUSIONS: Despite increased emphasis on the importance of PROs in AF, a minority of registered clinical trials reported collecting PROs, with very few using validated, AF-specific PROs. Improving outcomes that are most important to patients will necessitate increased emphasis on these PROs in pivotal clinical studies.
OBJECTIVES: This study sought to determine how frequently patient-reported outcomes (PROs) are collected in registered clinical studies of atrial fibrillation (AF). BACKGROUND: Improving symptom burden and quality of life are important goals in the treatment of AF and are best measured with PROs. METHODS: Data from Clincaltrials.gov were studied to identify PROs in AF studies. All studies reporting AF as the disease condition were included, and PROs were identified by search terms within the outcome measures field. Generic and AF-specific PROs were identified and assessed by study type and year. Clinicaltrials.gov reporting was compared with published reports of linked studies in PubMed. RESULTS: From 1999 to 2018, 1,709 studies including AFpatients were posted; 238 studies (14%) included PROs. Collection of PROs was reported in 22% of trials (n = 83 of 386) studying procedural interventions and 11% of all Phase 3 studies (n = 18 of 168). Among the 238 studies with PROs, most described "quality of life" (n = 194 [82%]), and most (n = 198 [83%]) included only generic (not AF-specific) PROs. Only 17% of studies (n = 40) reporting PROs specified a previously published AF-specific tool, most commonly the AFEQT (Atrial Fibrillation Effect on QualiTy-of-life) form (n = 20 [8.4%]). Among the available PubMed citations of 391 studies, 74 studies (19%) described collecting a specific PRO tool (n = 29 [7.4%]) for an AF-specific PRO. CONCLUSIONS: Despite increased emphasis on the importance of PROs in AF, a minority of registered clinical trials reported collecting PROs, with very few using validated, AF-specific PROs. Improving outcomes that are most important to patients will necessitate increased emphasis on these PROs in pivotal clinical studies.
Authors: P Dorian; W Jung; D Newman; M Paquette; K Wood; G M Ayers; J Camm; M Akhtar; B Luderitz Journal: J Am Coll Cardiol Date: 2000-10 Impact factor: 24.094
Authors: Anita Wokhlu; Kristi H Monahan; David O Hodge; Samuel J Asirvatham; Paul A Friedman; Thomas M Munger; David J Bradley; Christine M Bluhm; Janis M Haroldson; Douglas L Packer Journal: J Am Coll Cardiol Date: 2010-05-25 Impact factor: 24.094
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: Circulation Date: 2014-03-28 Impact factor: 29.690
Authors: John Spertus; Paul Dorian; Rosemary Bubien; Steve Lewis; Donna Godejohn; Matthew R Reynolds; Dhanunjaya R Lakkireddy; Alan P Wimmer; Anil Bhandari; Caroline Burk Journal: Circ Arrhythm Electrophysiol Date: 2010-12-15
Authors: Jonathan P Piccini; Renato D Lopes; Melissa H Kong; Vic Hasselblad; Kevin Jackson; Sana M Al-Khatib Journal: Circ Arrhythm Electrophysiol Date: 2009-12
Authors: Carlos A Morillo; Atul Verma; Stuart J Connolly; Karl H Kuck; Girish M Nair; Jean Champagne; Laurence D Sterns; Heather Beresh; Jeffrey S Healey; Andrea Natale Journal: JAMA Date: 2014-02-19 Impact factor: 56.272
Authors: Benjamin A Steinberg; Jeffrey Turner; Ann Lyons; Joshua Biber; Mihail G Chelu; James C Fang; Roger A Freedman; Frederick T Han; Benjamin Hardisty; Nassir F Marrouche; Ravi Ranjan; Rashmee U Shah; John A Spertus; Josef Stehlik; Brian Zenger; Jonathan P Piccini; Rachel Hess Journal: Europace Date: 2020-03-01 Impact factor: 5.214
Authors: Katherine S Allan; Theresa Aves; Shaunattonie Henry; Laura Banfield; J Charles Victor; Paul Dorian; Jeff S Healey; Jason G Andrade; Sandra L Carroll; Michael H McGillion Journal: CJC Open Date: 2020-04-02
Authors: Sana M Al-Khatib; Emelia J Benjamin; Christine M Albert; Alvaro Alonso; Cynthia Chauhan; Peng-Sheng Chen; Anne B Curtis; Patrice Desvigne-Nickens; Jennifer E Ho; Carolyn S P Lam; Mark S Link; Kristen K Patton; Margaret M Redfield; Michiel Rienstra; Yves Rosenberg; Renate Schnabel; John A Spertus; Lynne Warner Stevenson; Mellanie True Hills; Adriaan A Voors; Lawton S Cooper; Alan S Go Journal: Circulation Date: 2020-06-08 Impact factor: 29.690